Table 1.
Active Compound |
Structure | Polymers Used as Micellar Carriers |
Conclusions | Ref. |
---|---|---|---|---|
ANTI-AGEING | ||||
Oleanolic Acid | Poloxamer 407 | Enhanced wrinkle alleviation | [39] | |
CoQ10 | Oleyl-hyaluronan Hexyl-hyaluronan |
Enhancement in skin hydration | [40] | |
ACNE VULGARIS | ||||
All-trans Retinoic Acid (Tretinoin) | Poly(ethylene glycol) conjugated phosphatidylethanolamine | Higher stability with slower drug oxidation | [20] | |
All-trans Retinoic Acid (Tretinoin) | Diblock methoxy-poly(ethylene glycol)-poly(hexyl-substituted lactic acid) | Higher efficiency than marketed formulations | [41] | |
Adapalene | D-α-tocopheryl polyethyleneglycol 1000 succinate | Targeted drug delivery capacity Higher efficiency at lower dose than marketed formulations |
[42] | |
Benzoyl peroxide | Pluronic® F127 | Targeted drug delivery capacity | [43] | |
PSORIASIS | ||||
Tacrolimus | Diblock methoxy-poly(ethylene glycol)-poly(hexyl-substituted lactic acid) | Enhancement in skin drug deposition | [21] | |
Resveratrol | Pluronic® P123 Pluronic® F127 |
Decrease in the cytokine levels | [23] | |
Silibinin | - | Reduction of psoriasis index area | [44] | |
FUNGAL INFECTIONS | ||||
Clotrimazole Fluconazole |
Diblock Methoxy-poly(ethylene glycol)-poly(hexyl-substituted lactic acid) | Enhancement in skin drug deposition | [45] | |
Terconazole | Pluronic® P123 Pluronic® F127 Cremophor EL |
Higher permeation Higher skin deposition |
[46] | |
OTHER SKIN DISEASES AND CONDITIONS | ||||
Imiquimod | Diblock methoxy-poly(ethylene glycol)-)-hexyl-substituted lactide | Higher delivery efficiency at lower dose than the marketed formulation | [47] | |
Spironolactone | Diblock methoxy-poly(ethylene glycol)-poly(hexyl-substituted lactic acid) | Targeted drug delivery capacity | [48] |